

# Precision Medicine in Chronic Inflammation

8<sup>th</sup> International Clinical Symposium,  
July 1-2, 2022, Kiel, Germany

## AGENDA

Friday July 1, 2022

UKSH / AUDIMAX

**Morning: "Hands-on" courses at the UKSH**  
for further information please visit our website

**Special Interest Group-Meeting from Intercept**  
„PBC – NOT only a liver disease! An interdisciplinary overview“  
for further information please visit our website

Friday July 1, 2022

AUDIMAX, Kiel University / Room for exhibitions (Foyer)

Please note: times are given in CEST

■ Dermatology    ■ Gastroenterology    ■ Rheumatology    ■ Pneumology

Chair: Matthias Laudes (Kiel)

14:00 - 14:05	<b>Welcome to Kiel</b>	Simone Fulda (Kiel, DE)
14:05 - 14:10	<b>Welcome to Kiel</b>	Jens Scholz (Kiel, DE)
14:10 - 14:35	<b>Welcome to PMI</b>	Stefan Schreiber (Kiel, DE)

### THE RIGHT TARGET: ALLERGY OR BARRIER? (TANDEM TALKS)

Chairs: Alexander Scheffold (Kiel), Jens Humrich (Lübeck),  
Stefan Niemann (Borstel)

14:35 - 15:25	IL-1 to IL-36 - which cytokine is the best therapeutic target?	<span style="color: red;">■</span> <b>D:</b> Thomas Kündig (Zürich, CH) <span style="color: blue;">■</span> <b>G:</b> Florian Rieder (Cleveland, US) <span style="color: purple;">■</span> <b>R:</b> Torsten Witte (Hannover, DE) <span style="color: teal;">■</span> <b>P:</b> Guy Brusselle (Ghent, BE)
15:25 - 15:55	Chronic inflammation as a driver of the metabolic disorder and cardiovascular diseases	<span style="color: blue;">■</span> <b>G:</b> Marc Donath (Basel, CH) <span style="color: purple;">■</span> <b>R:</b> Nehal Mehta (Bethesda, US)
15:55 - 16:35	Biomarkers to direct selection of therapies - What can we expect?	<span style="color: red;">■</span> <b>D:</b> Johann E. Gudjonsson (Ann Arbor, US) <span style="color: blue;">■</span> <b>G:</b> Sebastian Zundler (Erlangen, DE) <span style="color: purple;">■</span> <b>R:</b> Denis Poddubnyy (Berlin, DE)
16:35 - 16:55	Microbiome: Magic target or magic delusion?	<span style="color: blue;">■</span> <b>G:</b> Andreas Stallmach (Jena, DE)
16:55 - 17:30	<b>Coffee break</b>	

### TARGETED THERAPIES THAT WILL SHAPE THE FUTURE: (TANDEM TALKS)

Chairs: Philip Rosenstiel (Kiel), Petra Bacher (Kiel),  
Christoph Lange (Borstel)

17:30 - 18:00	To be or not to be: Biosimilars vs. Originators	<span style="color: red;">■</span> <b>D:</b> Giampiero Girolomoni (Verona, IT) <span style="color: purple;">■</span> <b>R:</b> Bente Glintborg (Copenhagen, DN)
18:00 - 18:30	Oral versus Parenteral: who will win?	<span style="color: red;">■</span> <b>D:</b> Brian Kirby (Dublin, IE) <span style="color: blue;">■</span> <b>G:</b> Bruce Sands (New York, US)
18:30 - 19:00	Safety is the new efficacy?	<span style="color: purple;">■</span> <b>R:</b> Laura Coates (Oxford, GB) <span style="color: teal;">■</span> <b>P:</b> Christian Taube (Essen, DE)
19:00 - 19:50	Head-2-Head trials that have moved the field	<span style="color: red;">■</span> <b>D:</b> Andy Blauvelt (Oregon, US) <span style="color: blue;">■</span> <b>G:</b> David T. Rubin (Chicago, US) <span style="color: purple;">■</span> <b>R:</b> Désirée van der Heijde (Leiden, NL) <span style="color: teal;">■</span> <b>P:</b> Klaus F. Rabe (Großhansdorf, DE)

### END OF PROGRAM IN AUDIMAX / SHUTTLE TRANSFER PROVIDED

20:15 - 21:45 **Dinner at different locations / Shuttle Transfer provided**

### STATE-OF-THE-ART LECTURE AT „SANDHAFEN“ (KIEL FJORD)

Chair: Stefan Schreiber (Kiel)

Starting from 22:00  
- Official end 00:00    Informel Get-together

22:15 - 22:35    PMI-Cluster Lecture    Ben Krause-Kyora (Kiel, DE)

■ Dermatology ■ Gastroenterology ■ Rheumatology ■ Pneumology

Lecture Halls

**C**

**Frederik-Paulsen**

**D**

**A**

08:00 - 09:00

*Satellite Breakfast Symposia by Industry I*

09:00 - 09:15

**Welcome**

**EARLY CHOICES THAT DETERMINE PATIENT TRAJECTORIES**

Chairs:  
Diamant Thaçi (Lübeck)  
Stephan Weidinger (Kiel)

Chairs:  
Stefan Schreiber (Kiel)  
Jens Marquardt (Lübeck)

Chairs:  
Gabriela Riemekasten (Lübeck)  
Bimba F. Hoyer (Kiel)

Chairs:  
Jan Heyckendorf (Kiel)  
Klaus F. Rabe (Großhansdorf)

09:15 - 09:30

■ Early Case UKSH

■ Early Case UKSH

■ Early Case UKSH

■ Early Case UKSH

09:30 - 09:45

■ Conventional therapies: still a place in the therapeutic armamentarium?

■ Conventional Therapy: Benefits and Limits

■ Early diagnosis in rheumatoid arthritis: future directions

■ How to treat Asthma and COPD in 2022

Melinda Gooderham (Peterborough, CA)

Axel Dignaß (Frankfurt, DE)

Gerd Burmester (Berlin, DE)

Klaus F. Rabe (Großhansdorf, DE)

09:45 - 10:00

■ AD from topical to systemic treatment and back

■ Long term goals

■ Enthesitis and psoriasis arthritis: what are the best current and future ways for early diagnosis and treatment?

■ Inflammation and Exacerbations of Asthma and COPD

Dirk Jan Hijnen (Rotterdam, NL)

James Lindsay (London, GB)

Dirk Elewaut (Ghent, BE)

Wisia Wedzicha (London, GB)

10:00 - 10:15

■ Systemics: stopping or commitment forever?

■ Biologics: stopping or commitment forever?

■ Spondyloarthritis: how to improve early diagnosis and therapies? What comes next?

■ Infectious complications in COPD/Asthma patients

Mette Deleuran (Aarhus, DK)

Britta Siegmund (Berlin, DE)

Robert Landewé (Amsterdam, NL)

Sebastian Johnston (London, GB)

10:15 - 10:30

Discussion

Discussion

Discussion

Discussion

10:30 - 10:45

**Coffee break**

**BEST CHOICE OF THERAPY FOR COMPLEX PATIENTS**

Chairs:  
Sascha Gerdes (Kiel)  
Diamant Thaçi (Lübeck)

Chairs:  
Bernd Bokemeyer (Minden)  
Jens Marquardt (Lübeck)

Chairs:  
Bimba F. Hoyer (Kiel)  
Gabriela Riemekasten (Lübeck)

Chairs:  
Jan Heyckendorf (Kiel)  
Klaus F. Rabe (Großhansdorf)

10:45 - 11:00

■ Late Case UKSH

■ Late Case UKSH

■ Late Case UKSH

■ Late Case UKSH

11:00 - 11:15

■ What really matters: PRO vs. objective endpoints

■ What really matters: PRO vs. objective endpoints

■ Limitations in the current therapies of rheumatic arthritis: What comes next?

■ From genes to lung function in Asthma and COPD

Andrew Pink (London, GB)

Ellen J. Scherl (New York, US)

Laura Coates (Oxford, GB)

John Holloway (Southampton, GB)

11:15 - 11:30

■ Treatment targets versus disease control

■ Long term goals in complex patients: Combination as a solution?

■ Spondyloarthritis: decision trees in present and future

■ Choice of biologics for complex Asthma patients

Kilian Eyerich (Freiburg, DE)

Alexander Moschen (Linz, AT)

Rik Lories (Leuven, BE)

Andrew Menzies-Gow (London, GB)

11:30 - 11:45

■ What is new and in pipeline?

■ T2T versus disease control

■ Psoriasis arthritis as interdisciplinary challenge: how to select best individual therapies?

■ Rehabilitation in COPD/Asthma patients following COVID

Thomas Bieber (Bonn, DE)

Walter Reinisch (Vienna, AT)

Gerd Burmester (Berlin, DE)

Rembert Koczulla (Marburg & Schönau a. Königsee, DE)

11:45 - 12:00

Discussion

Discussion

Discussion

Discussion

12:00 - 12:05

**Lunch boxes & coffee**

12:05 - 13:05

*Satellite Lunch Symposia by Industry II*

13:05 - 13:10

**Lunch boxes & coffee**

13:10 - 14:10

*Satellite Lunch Symposia by Industry III*

14:10 - 14:15

**Coffee**

Chair: Diamant Thaçi (Lübeck), Stefan Schreiber (Kiel)

**- Frederik-Paulsen Hall -**

14:15 - 14:45

Pregnancy, Lactation, and Family Planning (tandem talk)

■ G: Ole Haagen Nielsen (Copenhagen, DK)

■ R: Christof Specker (Essen, DE)

14:45 - 15:15

Overlooked systematic manifestations in skin and joint - missed targets to establish long-term health? (tandem talk)

■ D: Wolf-Henning Boehncke (Geneva, CH)

■ R: Costantino Pitzalis (London, GB)

15:15 - 15:30

**Finishing Words to Main Program**

at 16:00 on time

Transfer buses to Hamburg Airport and Kiel Main Station

# Satellite Symposia by Industry I - III

Please note: times are given in CEST

■ Dermatology  
 ■ Gastroenterology  
 ■ Rheumatology  
 ■ Pneumology

Lecture Halls

**C**

*Frederik-Paulsen*

**D**

**A**

## Satellite Symposia I



08:00 - 09:00

Symposia with breakfast bags

**LILLY**



What do we need to know about drug-drug interactions in RA and AD?

Chair:

Diamant Thaçi (Lübeck, DE)

Diamant Thaçi (Lübeck, DE)  
 Torsten Witte (Hannover, DE)  
 Ingolf Cascorbi (Kiel, DE)

**GALÁPAGOS**



JAK-Inhibition in ulcerative colitis - remission revisited

Axel Dignaß (Frankfurt, DE)  
 Stefan Schreiber (Kiel, DE)  
 Andreas Sturm (Berlin, DE)  
 Dominik Bettenworth (Münster, DE)

**BRISTOL MYERS SQUIBB**



CharacteristYKs of potential future oral therapies in psoriasis

Wolf-Henning Boehncke (Geneva, CH)  
 Sascha Gerdes (Kiel, DE)

**PFIZER**



Antiviral COVID-19 therapy for high-risk patients - avoiding hospitalization

Chair:

Thomas Bahmer (Kiel, DE)

Thomas Bahmer (Kiel, DE)  
 Eike Hansen (Kiel, DE)

## Satellite Symposia II



12:05 - 13:05

Symposia with coffee & lunchbags part 1

**GALÁPAGOS**



Patients with rheumatoid arthritis - (put) through their paces

Bimba F. Hoyer (Kiel, DE)  
 Gabriela Riemekasten (Lübeck, DE)  
 Eva Schwaneck (Hamburg, DE)

**BRISTOL MYERS SQUIBB**



Advanced therapies in ulcerative colitis - what can we learn from neurology?

Tanja Kühbacher (Nürtingen, DE)  
 Ulf Helwig (Oldenburg, DE)  
 Klarissa Hanja Stürner (Kiel, DE)

**ABBVIE**



Disease Control at all Levels with JAK1-Inhibitors? - Unachievable?

Chair:

Walter Reinisch (Vienna, AT)

Stefan Schreiber (Kiel, DE)  
 Stephan Weidinger (Kiel, DE)  
 Torsten Witte (Hannover, DE)

**NOVARTIS**



IL-17A - a major player in the psoriatic disease spectrum

Ulrich Mrowietz (Kiel, DE)  
 Gerd Burmester (Berlin, DE)

## Satellite Symposia III



13:10 - 14:10

Symposia with coffee & lunchbags part 2

**LILLY**



Urgently address urgency in ulcerative colitis

Chair:

Axel Dignaß (Frankfurt, DE)

Axel Dignaß (Frankfurt, DE)  
 Walter Reinisch (Vienna, AT)  
 Konrad Aden (Kiel, DE)

**PFIZER**



10 years of JAK inhibition and beyond - Retrospect, present and what does it mean for the future?

Chair:

Stefan Schreiber (Kiel, DE)

Bimba F. Hoyer (Kiel, DE)  
 Stefan Schreiber (Kiel, DE)  
 Diamant Thaçi (Lübeck, DE)